Goldman Sachs Report Questions Financial Sustainability of Curative Gene Therapies

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering 'gene therapy' treatment: cures could be bad for business in the long run.

'Is curing patients a sustainable business model?' analysts ask in an April 10 report entitled 'The Genome Revolution.'

'The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing.'

'However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies.'